{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T05:48:54Z","timestamp":1781761734685,"version":"3.54.5"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Eltrombopag (EPAG) is an oral thrombopoietin receptor agonist analog with the potential risk to induce liver injury. This prospective registry study evaluated the prevalence and severity of hepatic injury in Chinese patients with severe aplastic anemia undergoing low-dose EPAG treatment (75\u00a0mg\/day) in the context of standard immunosuppressive therapy (IST). The incidence of acute drug-induced liver injury was slightly higher in the IST\u2009+\u2009EPAG group than in the IST group at the 1st and 2nd month, but no statistically significant difference was observed: 10% vs 5% (<jats:italic>p<\/jats:italic>\u2009=\u20090.400), 9% vs 8% (<jats:italic>p<\/jats:italic>\u2009=\u20091.000). At the 1st month, the incidences of alanine aminotransferase, aspartate aminotransferase, and total bilirubin increased of grade 3 or higher in the IST\u2009+\u2009EPAG and the IST groups, were 5% vs 3% (<jats:italic>p<\/jats:italic>\u2009=\u20090.228), 2% vs 1% (<jats:italic>p<\/jats:italic>\u2009=\u20091.000), 2% vs 1% (<jats:italic>p<\/jats:italic>\u2009=\u20091.000), respectively. The logistic analysis indicated that serum ferritin level was associated with severe liver injury events. There was a slight increase in the incidence of severe hepatic injury events in the patients with SAA treated by EPAG, but it was insignificant.<\/jats:p>","DOI":"10.1007\/s00277-025-06210-7","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T21:04:06Z","timestamp":1738789446000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Combining immunosuppressive therapy with low dosage eltrombopag in Chinese patients with severe aplastic anemia: mild aggravation of hepatic injury"],"prefix":"10.1007","author":[{"given":"Xiaoyu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingling","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ChengTao","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingnan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baodong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuemin","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangsheng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"key":"6210_CR1","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1056\/NEJMra1413485","volume":"379","author":"NS Young","year":"2018","unstructured":"Young NS (2018) Aplastic Anemia. N Engl J Med 379:1643\u20131656. https:\/\/doi.org\/10.1056\/NEJMra1413485","journal-title":"N Engl J Med"},{"issue":"3","key":"6210_CR2","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/bjh.19236","volume":"204","author":"A Kulasekararaj","year":"2024","unstructured":"Kulasekararaj A, Cavenagh J, Dokal I et al (2024) Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline. Br J Haematol 204(3):784\u2013804. https:\/\/doi.org\/10.1111\/bjh.19236","journal-title":"Br J Haematol"},{"key":"6210_CR3","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1634\/stemcells.2008-0366","volume":"27","author":"CL Erickson-Miller","year":"2009","unstructured":"Erickson-Miller CL, Delorme E, Tian S-S et al (2009) Preclinical Activity of Eltrombopag (SB-497115), an Oral, Nonpeptide Thrombopoietin Receptor Agonist. Stem Cells 27:424\u2013430. https:\/\/doi.org\/10.1634\/stemcells.2008-0366","journal-title":"Stem Cells"},{"issue":"19","key":"6210_CR4","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1182\/blood-2018-11-884486","volume":"133","author":"LJ Alvarado","year":"2019","unstructured":"Alvarado LJ, Huntsman HD, Cheng H et al (2019) Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-\u03b3. Blood 133(19):2043\u20132055. https:\/\/doi.org\/10.1182\/blood-2018-11-884486","journal-title":"Blood"},{"key":"6210_CR5","unstructured":"Park T (2008) Product Information. PROMACTA (eltrombopag). Promacta. Package insert (eltrombopag). Medically reviewed by Drugs.com. Last updated on Jul 29, 2024. https:\/\/www.drugs.com\/pro\/promacta.html. Accessed 11\/12\/2024"},{"key":"6210_CR6","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S0140-6736(10)60959-2","volume":"377","author":"G Cheng","year":"2011","unstructured":"Cheng G, Saleh MN, Marcher C et al (2011) Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. The Lancet 377:393\u2013402. https:\/\/doi.org\/10.1016\/S0140-6736(10)60959-2","journal-title":"The Lancet"},{"key":"6210_CR7","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1182\/blood-2017-04-748707","volume":"130","author":"RSM Wong","year":"2017","unstructured":"Wong RSM, Saleh MN, Khelif A et al (2017) Safety and efficacy of long-term treatment of chronic\/persistent ITP with eltrombopag: final results of the EXTEND study. Blood 130:2527\u20132536. https:\/\/doi.org\/10.1182\/blood-2017-04-748707","journal-title":"Blood"},{"key":"6210_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1200931","volume":"367","author":"MJ Olnes","year":"2012","unstructured":"Olnes MJ, Scheinberg P, Calvo KR et al (2012) Eltrombopag and Improved Hematopoiesis in Refractory Aplastic Anemia. N Engl J Med 367:11\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1200931","journal-title":"N Engl J Med"},{"key":"6210_CR9","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1182\/blood-2013-10-534743","volume":"123","author":"R Desmond","year":"2014","unstructured":"Desmond R, Townsley DM, Dumitriu B et al (2014) Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood 123:1818\u20131825. https:\/\/doi.org\/10.1182\/blood-2013-10-534743","journal-title":"Blood"},{"issue":"5","key":"6210_CR10","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1177\/2040620717693573","volume":"8","author":"H Gill","year":"2017","unstructured":"Gill H, Wong RSM, Kwong Y-L (2017) From chronic immune thrombocytopenia to severe aplastic anemia: recent insights into the evolution of eltrombopag. Therapeutic advances in hematology 8(5):159\u2013174. https:\/\/doi.org\/10.1177\/2040620717693573","journal-title":"Therapeutic advances in hematology"},{"key":"6210_CR11","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1080\/09537104.2020.1847267","volume":"33","author":"X Liu","year":"2022","unstructured":"Liu X, Hou M, Li J et al (2022) Efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia: stage 2 results from a multicenter phase III study. Platelets 33:82\u201388. https:\/\/doi.org\/10.1080\/09537104.2020.1847267","journal-title":"Platelets"},{"key":"6210_CR12","doi-asserted-by":"publisher","first-page":"6419","DOI":"10.21037\/apm-21-1067","volume":"10","author":"P Zhang","year":"2021","unstructured":"Zhang P, Miao W (2021) Eltrombopag-induced liver dysfunction during the treatment of immune thrombocytopenia and its risk factors. Ann Palliat Med 10:6419\u20136424. https:\/\/doi.org\/10.21037\/apm-21-1067","journal-title":"Ann Palliat Med"},{"key":"6210_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin SK, Kumar M, Lau GK et al (2016) Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 10:1\u201398. https:\/\/doi.org\/10.1007\/s12072-015-9675-4","journal-title":"Hepatol Int"},{"key":"6210_CR14","doi-asserted-by":"publisher","first-page":"s104","DOI":"10.7861\/clinmedicine.16-6-s104","volume":"16","author":"D Katarey","year":"2016","unstructured":"Katarey D, Verma S (2016) Drug-induced liver injury. Clin Med 16:s104\u2013s109. https:\/\/doi.org\/10.7861\/clinmedicine.16-6-s104","journal-title":"Clin Med"},{"key":"6210_CR15","unstructured":"(2017) Common Terminology Criteria for Adverse Events (CTCAE). https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf. Accessed 11\/12\/2024"},{"key":"6210_CR16","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.m2021.0290","author":"N Gattermann","year":"2021","unstructured":"Gattermann N, Muckenthaler MU, Kulozik AE et al (2021) The evaluation of iron deficiency and iron overload. Dtsch Arztebl Int. https:\/\/doi.org\/10.3238\/arztebl.m2021.0290","journal-title":"Dtsch Arztebl Int"},{"key":"6210_CR17","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1182\/blood-2016-10-740241","volume":"130","author":"E Vlachodimitropoulou","year":"2017","unstructured":"Vlachodimitropoulou E, Chen Y-L, Garbowski M et al (2017) Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator. Blood 130:1923\u20131933. https:\/\/doi.org\/10.1182\/blood-2016-10-740241","journal-title":"Blood"},{"key":"6210_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2109965","volume":"386","author":"R Peffault De Latour","year":"2022","unstructured":"Peffault De Latour R, Kulasekararaj A, Iacobelli S et al (2022) Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia. N Engl J Med 386:11\u201323. https:\/\/doi.org\/10.1056\/NEJMoa2109965","journal-title":"N Engl J Med"},{"issue":"11","key":"6210_CR19","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1007\/s00277-022-04966-w","volume":"101","author":"Y Jin","year":"2022","unstructured":"Jin Y, Li R, Lin S, et al (2022) A real-word experience of eltrombopag plus rabbit antithymocyte immunoglobulin-based IST in Chinese patients with severe aplastic anemia. Ann Hematol. 2022;101(11):2413\u20132419. 101(11), 2413\u20132419. https:\/\/doi.org\/10.1007\/s00277-022-04966-w","journal-title":"Ann Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06210-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06210-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06210-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T21:04:09Z","timestamp":1738789449000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06210-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":19,"alternative-id":["6210"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06210-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,5]]},"assertion":[{"value":"14 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving human participants were reviewed and approved by the Ethics Committee of Jiangsu Provincial People\u2019s Hospital the First Affiliated Hospital of Nanjing Medical University\/ Jiangsu Provincial People\u2019s Hospital (ChiCTR2100045895) (Ethical approval No. 2020-SR-548). The patients\/participants provided their written informed consent to participate in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}